What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the KEYNOTE-564 trial indicates that pembrolizumab improves disease-free survival (DFS) compared to placebo, with a hazard ratio of 0.63. However, the data is described as immature, which introduces some uncertainty regarding the long-term effectiveness. While there is a moderate benefit shown, the lack of mature data prevents a higher rating.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for pembrolizumab are within the range that NICE considers acceptable for Healthcare resources. The committee concluded that the ICERs, even with some uncertainty, support its use as a cost-effective option for adjuvant treatment.
Is there quality-of-life evidence payers weigh? — Quality of life
The document discusses the side effects of current treatments for renal cell carcinoma, which can severely affect quality of life. However, it does not provide specific data on HRQoL improvements associated with pembrolizumab. The absence of validated tools or significant evidence of quality-of-life gains leads to a rating of minimal impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
While there are more grade 3 to 5 adverse events reported with pembrolizumab compared to placebo, the committee acknowledged that this is expected with active immunotherapy. The overall safety profile is acceptable, with manageable adverse events, justifying a good rating.
Was the drug compared against what payers expect? — Comparator Selection
Pembrolizumab was compared against placebo in a well-designed phase 3 trial, which is appropriate for assessing its effectiveness. The committee found the comparator selection to be strong, with no significant gaps.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is aligned with the marketing authorization, focusing on adults with renal cell carcinoma at increased risk of recurrence after nephrectomy. The committee found the population to be generalizable to the Healthcare, supporting a good rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Pembrolizumab can be integrated into existing treatment pathways with minor adjustments, such as routine surveillance. The committee noted that the treatment regimen is manageable within current clinical practice, justifying a strong rating.
Are the wider system costs understood? — Resource Use and Cost Implications
The document indicates that pembrolizumab is likely to be cost-effective and manageable within Healthcare budgets, with a commercial arrangement providing a discount. This suggests a favorable impact on resource use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a phase 3 RCT, which is a strong design. However, the immaturity of the data introduces some concerns about robustness. Overall, the evidence quality is acceptable but not without limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term effectiveness of pembrolizumab, particularly concerning the duration of treatment effects and the risk of relapse. This uncertainty may affect its broader impacts and decision-making.
